Celsion Corporation (CLSN), Acasti Pharma (ACST) and Heat Biologics (HTBX) Emerge as Losers among Biotech Stocks
Being an oncology drug development company,An agreement for load between Celsion Corporation (NASDAQ:CLSN) and Hercules Technology Growth Capital, Inc., has been signed; the loan will allow $20 million in capital distributable. With the agreement’s closing on the 25th of November, Celsion Corporation (NASDAQ:CLSN) got its first tranche worth $5 million. Shares of Celsion Corporation (NASDAQ:CLSN) ended at a value of $36.56 yesterday. Institutional ownership of the stock is 15.00% whereas its insider ownership is 0.80%. Stock’s shares capital has outstanding shares of 12.09 billion out of which shares of 13.38 billion are being floated in the market.
An IPO of 16 million Acasti units at a value of $1.25 a unit will be held by Acasti Pharma Inc (NASDAQ:ACST). Each unit at IPO will have a purchase warrant for one share from Class A and one from Common Share of Acasti Pharma Inc (NASDAQ:ACST). Shares of Acasti Pharma Inc (NASDAQ:ACST) kicked off its day’s session at $1.28 and went up as high as $1.28; after dipping by -13.68% towards the session’s end the stock closed at a value of $1.20. Stock’s weekly performance was -22.58%.
Heat Biologics Inc (NASDAQ:HTBX) has successfully completed its investigational GMP-grade batch of HS-410 drug. Shares of Heat Biologics Inc (NASDAQ:HTBX) had a volume share of 46,432.00 during the session’s trading where its average volume share is 31,250.00. Shares of Heat Biologics Inc (NASDAQ:HTBX) kicked off at a value of $9.18 and went up as high as $9.30; after dipping by -8.62% the stock closed at $8.38.